News
The settlement agreement will extend market exclusivity for AbbVie's JAK inhibitor in the U.S. until 2037—providing pediatric ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible resultsSome results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback